When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Nearly three quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...

The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...